Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open Label Study of Safety/Tolerability of Once Nightly FT218 for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy Patients That Have and Have Not Been Previously Maintained on Twice-nightly Sodium Oxybate IR

Next Previous
Trial Profile

Open Label Study of Safety/Tolerability of Once Nightly FT218 for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy Patients That Have and Have Not Been Previously Maintained on Twice-nightly Sodium Oxybate IR

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sodium oxybate (Primary) ; Sodium oxybate
  • Indications Cataplexy; Narcolepsy
  • Focus Adverse reactions; Registrational
  • Acronyms RESTORE
  • Sponsors Avadel Pharmaceuticals

Most Recent Events

  • 03 Sep 2024 According to an Avadel Pharmaceuticals media release, data from this trial were published in the Sleep Medicine: X.
  • 03 Sep 2024 Results presented in the Avadel Pharmaceuticals Media Release.
  • 22 May 2024 According to an Avadel Pharmaceuticals media release, end-of-study survey data from this trial will be presented at the SLEEP 2024, the 38th annual joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society on June 1-5, 2024, in Houston.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top